Vol 52, No 3 (2021)
Clinical vignette
Published online: 2021-04-28
A dream that came true: Poland’s first successful CAR-T cell therapy in child with refractory B-cell acute lymphoblastic leukemia (ALL)
Acta Haematol Pol 2021;52(3):211-213.
Abstract
Not available
Keywords: CAR-T cell therapyacute lymphoblastic leukemia
References
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–448.
- Cope S, Ayers D, Zhang J, et al. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019; 19(1): 182.
- Diorio C, Maude SL. CAR T cells vs allogeneic HSCT for poor-risk ALL. Hematology Am Soc Hematol Educ Program. 2020; 2020(1): 501–507.
- Styczyński J. Where dreams come true: CAR-T cell therapy in Poland! Acta Haematologica Polonica. 2020; 51(1): 1.
- Dytfeld D, Łojko-Dankowska A, Matuszak M, et al. Road to clinical implementation of CAR-T technology in Poznań. Acta Haematologica Polonica. 2020; 51(1): 24–28.
- Styczyński J. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica. 2020; 51(1): 2–5.
- Gil L, Łojko-Dankowska A, Matuszak M, et al. CAR-T cell therapy — toxicity and its management. Acta Haematologica Polonica. 2020; 51(1): 6–10.
- Styczyński J. Infections following CAR-T cells therapy: current state-of-the-art review and recommendations. Acta Haematologica Polonica. 2020; 51(1): 11–16.
